410 related articles for article (PubMed ID: 17877845)
1. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
2. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
[TBL] [Abstract][Full Text] [Related]
4. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N; Dhodapkar MV
Clin Adv Hematol Oncol; 2009 Oct; 7(10):677-81, 687-90. PubMed ID: 20040909
[TBL] [Abstract][Full Text] [Related]
5. Current and future therapeutic approach for Waldenström's macroglobulinemia.
Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
[TBL] [Abstract][Full Text] [Related]
7. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz R; Tedeschi A
Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
[TBL] [Abstract][Full Text] [Related]
8. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
9. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
10. Role of proteasome inhibition in Waldenström's macroglobulinemia.
Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
12. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
[TBL] [Abstract][Full Text] [Related]
13. Prognosis and treatment of Waldenström's macroglobulinemia.
Louw VJ; Webb MJ
Transfus Apher Sci; 2010 Apr; 42(2):193-7. PubMed ID: 20117052
[TBL] [Abstract][Full Text] [Related]
14. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
15. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Mailankody S; Landgren O
Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
[TBL] [Abstract][Full Text] [Related]
17. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.
Ni H; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Hitoshi Y; Ansell SM; Treon SP; Thomas SK; Lee HC; Wang Z; Davis RE; Orlowski RZ
Clin Cancer Res; 2018 Dec; 24(24):6408-6420. PubMed ID: 30126942
[TBL] [Abstract][Full Text] [Related]
18. Lymphoplasmacytic lymphoma with IgA paraproteinemia mimicking Waldenstrom's Macroglobulinemia.
Basu D; Pathak D; Shyambabu C; Koner BC; Swaminathan RP
Indian J Pathol Microbiol; 2004 Oct; 47(4):515-7. PubMed ID: 16295380
[TBL] [Abstract][Full Text] [Related]
19. Bilateral, persistent serous macular detachments with Waldenström's macroglobulinemia.
Pilon AF; Rhee PS; Messner LV
Optom Vis Sci; 2005 Jul; 82(7):573-8. PubMed ID: 16044069
[TBL] [Abstract][Full Text] [Related]
20. Waldenstrom's macroglobulinemia in the era of immunotherapy.
Vaxman I; Gertz M
Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
